Kraszewska Zuzanna, Skowron Krzysztof, Kwiecińska-Piróg Joanna, Grudlewska-Buda Katarzyna, Przekwas Jana, Wiktorczyk-Kapischke Natalia, Wałecka-Zacharska Ewa, Gospodarek-Komkowska Eugenia
Department of Microbiology, Nicolaus Copernicus University in Toruń, L. Rydygier Collegium Medicum in Bydgoszcz, 9 M. Skłodowska-Curie St., 85-094 Bydgoszcz, Poland.
Department of Food Hygiene and Consumer Health, Wrocław University of Environmental and Life Sciences, 50-375 Wrocław, Poland.
Antibiotics (Basel). 2022 Dec 3;11(12):1749. doi: 10.3390/antibiotics11121749.
Urinary Tract Infections (UTIs) are common outpatient and inpatient infections, often treated with empirical therapy. spp. is responsible for about 10% of UTIs. This study aimed to determine the necessity of changing the empirical treatment of UTIs caused by spp. The evaluation was performed for 542 strains isolated from urine samples in the years 2016-2021. We identified three species that were found: (389, 71.8%), (151, 27.8%) and (2, 0.4%). was the dominant species every year. Among the most prevalent was resistance to norfloxacin (51.4%). Almost all strains (150, 99.3%) were resistant to beta-lactams and norfloxacin. Eighty-three strains (55.0%) were resistant to vancomycin and 72 (47.7%) to teicoplanin. strains showed a significantly higher percentage of resistance mechanisms GRE (Glicopeptide-Resistant ) (72, 48.7%) and VRE (Vancomycin-Resistant ) (11, 7.3%), while only five strains of showed a VRE mechanism (1.3%). In the therapy of UTIs, ampicillin and imipenem still remain effective. However, the above-mentioned antibiotics, as well as fluoroquinolones, are not recommended in the treatment of UTIs of etiology.
尿路感染(UTIs)是常见的门诊和住院感染,通常采用经验性治疗。某菌属导致约10%的尿路感染。本研究旨在确定改变由该菌属引起的尿路感染经验性治疗的必要性。对2016年至2021年从尿液样本中分离出的542株菌株进行了评估。我们鉴定出三种该菌属物种:某菌1(389株,71.8%)、某菌2(151株,27.8%)和某菌3(2株,0.4%)。某菌1每年都是优势菌种。在某菌属中,最常见的是对诺氟沙星耐药(51.4%)。几乎所有某菌2菌株(150株,99.3%)对β-内酰胺类和诺氟沙星耐药。83株(55.0%)对万古霉素耐药,72株(47.7%)对替考拉宁耐药。某菌2菌株显示出耐药机制糖肽类耐药肠球菌(GRE)(72株,48.7%)和耐万古霉素肠球菌(VRE)(11株,7.3%)的比例显著更高,而只有5株某菌1显示出VRE机制(1.3%)。在治疗某菌2尿路感染时,氨苄西林和亚胺培南仍然有效。然而,上述抗生素以及氟喹诺酮类不推荐用于治疗某菌1病因的尿路感染。